- Home
- ORKA vs RIGL Comparison
ORKA vs RIGL Comparison
Compare ORKA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- RIGL
- Stock Information
- Founded
- ORKA 2004
- RIGL 1996
- Country
- ORKA United States
- RIGL United States
- Employees
- ORKA N/A
- RIGL N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- RIGL Health Care
- Exchange
- ORKA Nasdaq
- RIGL Nasdaq
- Market Cap
- ORKA 429.4M
- RIGL 366.5M
- IPO Year
- ORKA N/A
- RIGL 2000
- Fundamental
- Price
- ORKA $8.92
- RIGL $17.66
- Analyst Decision
- ORKA Strong Buy
- RIGL Buy
- Analyst Count
- ORKA 7
- RIGL 5
- Target Price
- ORKA $39.67
- RIGL $36.80
- AVG Volume (30 Days)
- ORKA 272.6K
- RIGL 233.5K
- Earning Date
- ORKA 03-06-2025
- RIGL 05-06-2025
- Dividend Yield
- ORKA N/A
- RIGL N/A
- EPS Growth
- ORKA N/A
- RIGL N/A
- EPS
- ORKA N/A
- RIGL 0.99
- Revenue
- ORKA N/A
- RIGL $179,278,000.00
- Revenue This Year
- ORKA N/A
- RIGL $12.53
- Revenue Next Year
- ORKA N/A
- RIGL $15.68
- P/E Ratio
- ORKA N/A
- RIGL $17.83
- Revenue Growth
- ORKA N/A
- RIGL 54.71
- 52 Week Low
- ORKA $8.66
- RIGL $7.48
- 52 Week High
- ORKA $53.88
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- RIGL 38.38
- Support Level
- ORKA N/A
- RIGL $16.90
- Resistance Level
- ORKA N/A
- RIGL $18.30
- Average True Range (ATR)
- ORKA 0.00
- RIGL 1.09
- MACD
- ORKA 0.00
- RIGL -0.22
- Stochastic Oscillator
- ORKA 0.00
- RIGL 17.60
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.